Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Total Assets of $40.56 billion for the year ending 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +7.4% in Total Assets from 2024 to 2025.
- This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $790.64 million | Q3 2010: $942.43 million | Q1 2011: $1.07 billion | Q2 2011: $1.05 billion | Q3 2011: $983.03 million | Q1 2012: $1.35 billion | Q2 2012: $1.46 billion | Q3 2012: $1.66 billion | Q1 2013: $2.28 billion | Q2 2013: $2.38 billion | Q3 2013: $2.64 billion | Q1 2014: $3.26 billion | Q2 2014: $3.46 billion | Q3 2014: $3.74 billion | Q1 2015: $4.20 billion | Q2 2015: $4.53 billion | Q3 2015: $5.18 billion | Q1 2016: $5.90 billion | Q2 2016: $6.20 billion | Q3 2016: $6.83 billion | Q1 2017: $7.82 billion | Q2 2017: $8.11 billion | Q3 2017: $8.70 billion | Q1 2018: $9.37 billion | Q2 2018: $9.95 billion | Q3 2018: $10.81 billion | Q1 2019: $12.85 billion | Q2 2019: $13.17 billion | Q3 2019: $13.94 billion | Q1 2020: $15.76 billion | Q2 2020: $14.43 billion | Q3 2020: $16.08 billion | Q1 2021: $17.77 billion | Q2 2021: $21.49 billion | Q3 2021: $23.67 billion | Q1 2022: $26.35 billion | Q2 2022: $27.21 billion | Q3 2022: $27.68 billion | Q1 2023: $30.06 billion | Q2 2023: $30.66 billion | Q3 2023: $32.16 billion | Q1 2024: $34.37 billion | Q2 2024: $36.09 billion | Q3 2024: $37.44 billion | Q1 2025: $37.55 billion | Q2 2025: $38.22 billion | Q3 2025: $40.17 billion.
- Over the full 17 years of available data (2009 to 2025), REGENERON PHARMACEUTICALS, INC.'s Total Assets has grown by 5,372.0%.
- Historical annual values: Fiscal year 2025: $40.56 billion | Fiscal year 2024: $37.76 billion | Fiscal year 2023: $33.08 billion | Fiscal year 2022: $29.21 billion | Fiscal year 2021: $25.43 billion | Fiscal year 2020: $17.16 billion | Fiscal year 2019: $14.81 billion | Fiscal year 2018: $11.73 billion | Fiscal year 2017: $8.76 billion | Fiscal year 2016: $6.97 billion | Fiscal year 2015: $5.61 billion | Fiscal year 2014: $3.84 billion | Fiscal year 2013: $2.95 billion | Fiscal year 2012: $2.08 billion | Fiscal year 2011: $1.32 billion | Fiscal year 2010: $1.09 billion | Fiscal year 2009: $741.20 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: